KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Debt (2018 - 2022)

Historic Total Debt for TherapeuticsMD (TXMD) over the last 8 years, with Q3 2022 value amounting to $93.6 million.

  • TherapeuticsMD's Total Debt fell 4987.52% to $93.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $93.6 million, marking a year-over-year decrease of 4987.52%. This contributed to the annual value of $188.3 million for FY2021, which is 2079.49% down from last year.
  • TherapeuticsMD's Total Debt amounted to $93.6 million in Q3 2022, which was down 4987.52% from $90.8 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Total Debt peaked at $243.4 million during Q1 2020, and registered a low of $73.1 million during Q2 2018.
  • In the last 5 years, TherapeuticsMD's Total Debt had a median value of $186.7 million in 2021 and averaged $160.4 million.
  • In the last 5 years, TherapeuticsMD's Total Debt skyrocketed by 23119.02% in 2020 and then crashed by 5099.89% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Total Debt stood at $73.4 million in 2018, then skyrocketed by 165.24% to $194.6 million in 2019, then grew by 22.13% to $237.7 million in 2020, then dropped by 20.79% to $188.3 million in 2021, then tumbled by 50.28% to $93.6 million in 2022.
  • Its last three reported values are $93.6 million in Q3 2022, $90.8 million for Q2 2022, and $202.9 million during Q1 2022.